Compare Divis Laboratories with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NEULAND LABS - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NEULAND LABS DIVIS LABORATORIES/
NEULAND LABS
 
P/E (TTM) x 58.0 53.9 107.7% View Chart
P/BV x 15.5 4.1 380.6% View Chart
Dividend Yield % 0.4 0.1 444.3%  

Financials

 DIVIS LABORATORIES   NEULAND LABS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
NEULAND LABS
Mar-20
DIVIS LABORATORIES/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs1,639754 217.5%   
Low Rs1,115247 450.9%   
Sales per share (Unadj.) Rs186.3594.5 31.3%  
Earnings per share (Unadj.) Rs51.012.6 403.4%  
Cash flow per share (Unadj.) Rs57.337.0 154.9%  
Dividends per share (Unadj.) Rs16.002.00 800.0%  
Dividend yield (eoy) %1.20.4 290.7%  
Book value per share (Unadj.) Rs261.8553.4 47.3%  
Shares outstanding (eoy) m265.4712.83 2,069.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.40.8 878.0%   
Avg P/E ratio x27.039.6 68.2%  
P/CF ratio (eoy) x24.013.5 177.7%  
Price / Book Value ratio x5.30.9 581.7%  
Dividend payout %31.415.8 198.3%   
Avg Mkt Cap Rs m365,5926,421 5,693.9%   
No. of employees `00011.81.3 924.1%   
Total wages/salary Rs m5,4231,236 438.9%   
Avg. sales/employee Rs Th4,175.15,949.4 70.2%   
Avg. wages/employee Rs Th457.7963.8 47.5%   
Avg. net profit/employee Rs Th1,141.8126.4 903.2%   
INCOME DATA
Net Sales Rs m49,4637,627 648.5%  
Other income Rs m1,55639 4,005.9%   
Total revenues Rs m51,0197,666 665.5%   
Gross profit Rs m18,7181,019 1,837.2%  
Depreciation Rs m1,689313 540.0%   
Interest Rs m35216 16.2%   
Profit before tax Rs m18,551529 3,505.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023367 1,368.3%   
Profit after tax Rs m13,527162 8,346.1%  
Gross profit margin %37.813.4 283.3%  
Effective tax rate %27.169.4 39.0%   
Net profit margin %27.32.1 1,287.0%  
BALANCE SHEET DATA
Current assets Rs m46,5015,152 902.6%   
Current liabilities Rs m8,4683,576 236.8%   
Net working cap to sales %76.920.7 372.2%  
Current ratio x5.51.4 381.2%  
Inventory Days Days131105 124.5%  
Debtors Days Days8691 94.5%  
Net fixed assets Rs m25,7973,969 650.0%   
Share capital Rs m531129 411.6%   
"Free" reserves Rs m68,9626,971 989.3%   
Net worth Rs m69,4937,100 978.8%   
Long term debt Rs m0774 0.0%   
Total assets Rs m80,38312,310 653.0%  
Interest coverage x531.03.5 15,378.2%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 99.3%   
Return on assets %16.93.1 549.7%  
Return on equity %19.52.3 852.7%  
Return on capital %26.79.5 282.7%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,2385,187 795.1%   
Fx outflow Rs m12,4051,593 778.8%   
Net fx Rs m28,8333,594 802.3%   
CASH FLOW
From Operations Rs m9,543573 1,664.3%  
From Investments Rs m-6,854-487 1,408.0%  
From Financial Activity Rs m-2,459-55 4,488.0%  
Net Cashflow Rs m23033 704.3%  

Share Holding

Indian Promoters % 52.0 36.3 143.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 63.7 18.5%  
FIIs % 19.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 63.7 27.0%  
Shareholders   31,796 12,705 250.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


May 12, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - CADILA HEALTHCARE COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS